Takeda: Mezagitamab Phase 2 Trial Shows Positive Results In

Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) announced Wednesday positive topline results from a Phase 2 trial of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia or ITP.

Related Keywords

, Chinwe Ukomadu , More Such Health News , Takeda Pharmaceutical Co , Drug Administration , Takeda Pharmaceutical , Orphan Drug Designation , Fast Track , Inflammation Therapeutic Area Unit ,